India Pharma Outlook Team | Tuesday, 03 November 2026
Drug import rules stand ready for expansion as the center proposes wider gateways for drugs and medical devices under Rule 43A of the Drugs Rules, 1945.
The Union Health Ministry seeks to add new entry points so that pharmaceutical and medical device consignments can move through more locations.
This drug import proposal aims to ease logistics bottlenecks, improve cargo movement and place regulatory entry points closer to manufacturing and distribution hubs.
The changes remain proposals for now, and their real impact will depend on how authorities implement the revised network and support consistent clearance processes across the new sites.
Pharmaceutical imports currently rely on a limited set of authorized entry points that handle clearance under Rule 43A. Importers often route consignments through these designated ports and airports, which can create longer inland journeys and congestion. Expanding the drug import network would give companies more options for bringing goods into the country.
Proposed additions include Inland Container Depots at Sonipat, Piyala and Harsaru in Haryana, Dadri in Uttar Pradesh, Gandhidham/Mundra in Gujarat, Sanath Nagar and Thimmapur in Hyderabad, and Whitefield in Bengaluru.
The list also covers the Bommasandra Special Economic Zone in Karnataka and Noida International Airport in Uttar Pradesh for air imports. These locations sit nearer many manufacturing and warehouse clusters, which can shorten inland transport routes and ease pressure on traditional gateways.
Also Read: India's 30% Anti-Cancer Drug Margin Cap: What It Means for Pharma
Additional gateways can support smoother cargo movement and better coordination of clearance activities. Temperature-sensitive medicines specialized medical devices and other healthcare products stand to gain from routing flexibility that reduces long-distance road hauls. Importers and distributors can choose entry points closer to their facilities, which may cut handling steps and overall logistics complexity.
The ministry expects the expansion to minimize delays in the movement of imported medicines, medical devices, and cosmetics while improving regional availability. Clearance speed and cost outcomes will still depend on the readiness of customs and regulatory teams at each new location.
Medical device importers share the same proposed drug import network expansion. Access to inland depots, the Bommasandra SEZ and Noida International Airport can help companies serve different regional healthcare markets more efficiently. Diagnostic equipment, hospital supplies, and specialized technologies can move through points nearer end-user destinations.
Improved logistics support stronger healthcare supply chains, yet regulatory compliance and inspection standards remain mandatory at every authorized gateway. Authorities must maintain uniform quality oversight regardless of which entry point handles the consignment.
The proposal must convert into working arrangements before importers can capture the intended benefits. Customs coordination, drug regulatory infrastructure, inspection facilities, and trained personnel will decide whether the new sites function effectively. Consistent procedures across all designated locations remain essential so that quality controls stay intact.
Infrastructure readiness and disciplined execution will ultimately determine the commercial value of the expanded gateway network for pharmaceutical and medical device imports. The proposed expansion could reshape India's drug import logistics, but faster clearance and lower costs will depend on regulatory readiness and implementation.
.jpg)
